Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:16 pm
Share
Mirum Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 47.73 million compared to USD 18.78 million a year ago. Net loss was USD 23.59 million compared to USD 35.71 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 1.02 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to USD 1.02 a year ago.
For the nine months, revenue was USD 116.82 million compared to USD 49.16 million a year ago. Net loss was USD 127.76 million compared to USD 99.23 million a year ago. Basic loss per share from continuing operations was USD 3.28 compared to USD 3.03 a year ago. Diluted loss per share from continuing operations was USD 3.28 compared to USD 3.03 a year ago.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
MIRUM PHARMACEUTICALS, INC. 
